Rising Rheumatoid Arthritis Prevalence Fuels Tofacitinib Market Growth: A Significant Driver Propelling The Tofacitinib Market In 2025

The Tofacitinib Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Tofacitinib Market Size and Projected Growth Rate?
The Tofacitinib Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Tofacitinib Market Size and Projected Growth Rate?

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10779

What Are the Major Segments in the Tofacitinib Market?
The tofacitinib market covered in this report is segmented -

1) By Drug Class: Antirheumatic, Janus Kinase Inhibitor, Immunosuppressant
2) By Strength: 5mg, 10mg, 11mg, 22mg
3) By Route Of Administration: Oral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By Application: Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Other Applications

Subsegments:
1) By Antirheumatic: Conventional Synthetic Antirheumatics, Targeted Synthetic Antirheumatics
2) By Janus Kinase Inhibitor: JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors
3) By Immunosuppressant: Corticosteroids, Non-Steroidal Immunosuppressants

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10779&type=smp

What Are The Driving Tofacitinib Market Evolution?
The increasing occurrence of rheumatoid arthritis, an autoimmune, inflammatory disorder that impacts the hands, feet, joints, and internal organs, is foreseen to fuel the expansion of the tofacitinib market. Tofacitinib drugs work by inhibiting the Janus kinase enzymes from inflaming, which eventually leads to the symptoms of rheumatoid arthritis. For example, the National Arthritis Data Workgroup, a US-based group of epidemiology experts, reported in February 2022 that over 52.5 million adult Americans, which accounts for more than 22% of the population, have been diagnosed with arthritis or a related rheumatic disease. By 2030, the number of adults aged 18 and above with arthritis is projected to hit 67 million. Hence, the growing prevalence of rheumatoid arthritis is boosting the tofacitinib market's development.

Which Firms Dominate The Tofacitinib Market Segments?
Major companies operating in the tofacitinib market include Beacon Pharmaceuticals Limited, Pfizer Inc., Globe Pharmaceuticals Ltd., Drug International Limited, Dolphin Pharmaceuticals, Lancer Therapeutics, Glenmark Pharmaceuticals LTD., Sun Pharmaceutical Industries Ltd., Shandong Octagon Chemicals Limited, Zydus Lifesciences Ltd., Esteve Pharmaceuticals SA, Unichem Laboratories, Beijing Mesochem Technology Co. Ltd, Aprazer Healthcare Pvt Ltd, Apino Pharma Co Ltd, Delta Pharma Limited, Mediconlife, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd., Lupin Limited, Aurobindo Pharma Limited, Cipla Inc., Dr. Reddy's Laboratories Ltd., Jubilant Life Sciences, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited

What Trends Are Expected to Dominate the Tofacitinib Market in the Next 5 Years?
Leading corporations in the tofacitinib market are forging ahead with the development of innovative creams, such as the tofacitinib ointment, to bolster targeted delivery and boost patient results for those suffering from inflammatory skin diseases. Tofacitinib Ointment, being a topical JAK inhibitor, serves as a novel solution in the tofacitinib market by offering a steroid-free alternative for patients who have unmet medical requirements. For instance, in June 2023, the Indian-based company, Intas Pharmaceuticals Ltd., released tofatas, a DCGI-certified tofacitinib ointment (2% w/w) as a treatment for mild to moderate atopic dermatitis (AD) in adults. This product marked the first approved topical JAK inhibitor in India, highlighting innovation in therapy for the condition after a hiatus of 15 years. Besides availing a treatment option free from steroids, tofatas bridges a significant gap in treatment, potentially improving the life quality of patients and widening the scope of tofacitinib's use in dermatology.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/tofacitinib-global-market-report

Which Is The Largest Region In The Tofacitinib Market?
North America was the largest region in the tofacitinib market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Tofacitinib Market?
2. What is the CAGR expected in the Tofacitinib Market?
3. What Are the Key Innovations Transforming the Tofacitinib Industry?
4. Which Region Is Leading the Tofacitinib Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.